NCT06374212View on ClinicalTrials.gov

Anifrolumab for Hidradenitis Suppurativa

PHASE2RecruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

May 31, 2026

Conditions

Hidradenitis SuppurativaAcne InversaHidradenitis

Interventions

DRUG

Anifrolumab

900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20

Trial Locations (1)

27516

RECRUITING

UNC Dermatology and Skin Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER